[The change of intestinal mucosa barrier in chronic severe hepatitis B patients and clinical intervention]

Zhonghua Gan Zang Bing Za Zhi. 2009 Oct;17(10):754-8.
[Article in Chinese]

Abstract

Objective: To study the change of intestinal mucosa barrier in chronic severe hepatitis B patients and clinical intervention.

Method: (1) 30 normal healthy controls and 60 chronic severe hepatitis B patients were enrolled in this study. The change of intestinal permeability was determined by urine lactulose/ mannitol ratio (L/M), and the serum diamine oxidase (DAO) was measured. (2) 60 chronic severe hepatitis B patients were randomly divided into two groups: the control group and the treated group, each group has 30 cases. Patients in the control group received standard treatment for 2 weeks, however, in addition to standard treatment, patients in the treated group also received glutamine 10g tid. Endotoxin (ET), DAO and L/M were compared between the two group.

Results: (1) Compared to healthy controls, the level of L/M and DAO was significantly increased in chronic severe hepatitis B patients (t = 2.762, P less than 0.01 or t = 6.326, P less than 0.01). (2) Compared to the control group, ET, DAO and L/M were significantly lower 2 weeks after treatment (F = 11.662, P less than 0.01; F = 12.699, P less than 0.01; F = 19.981, P less than 0.01).

Conclusion: (1) There is an early intestinal mucosa barrier damage in chronic severe hepatitis B patients. (2) Compared to standard treatment, adding glutamine can reverse intestinal mucosa barrier damage.

Publication types

  • English Abstract
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Amine Oxidase (Copper-Containing) / blood
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Child
  • Endotoxins / blood
  • Female
  • Glutamine / pharmacology
  • Glutamine / therapeutic use*
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / metabolism
  • Hepatitis B, Chronic / physiopathology
  • Humans
  • Intestinal Mucosa / drug effects*
  • Intestinal Mucosa / metabolism
  • Intestinal Mucosa / physiopathology*
  • Intestine, Small
  • Lactulose / urine
  • Male
  • Mannitol / urine
  • Middle Aged
  • Permeability
  • Treatment Outcome
  • Young Adult

Substances

  • Antiviral Agents
  • Endotoxins
  • Glutamine
  • Mannitol
  • Lactulose
  • Amine Oxidase (Copper-Containing)